First Trust Multi Cap Growth AlphaDEX Fund (FAD) Price & Chart

Agilent (A) Technologies announced the SureSelect Cancer Research Pan Heme. Developed in collaboration with experts at Roswell Park Comprehensive Cancer Center, the solution integrates DNA and RNA profiling, automated sample

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

Guggenheim raised the firm’s price target on SharkNinja (SN) to $250 from $210 and keeps a Buy rating on the shares following what the firm calls a “broad-based 3Q beat

Piper Sandler raised the firm’s price target on Moderna (MRNA) to $305 from $230 and keeps an Overweight rating on the shares following the company’s earnings report. The firm anticipates

Cantor Fitzgerald analyst Ramsey El-Assal raised the firm’s price target on Corpay (CPAY) to $550 from $480 and keeps an Overweight rating on the shares. Published first on TheFly –

Goldman Sachs analyst Salveen Richter raised the firm’s price target on Moderna (MRNA) to $195 from $137 and keeps a Neutral rating on the shares. Moderna delivered a significant Q3

Moderna (MRNA) has disclosed a new risk, in the Share Price & Shareholder Rights category. Moderna faces potential dilution risk for existing stockholders if its convertible notes are exchanged for

BofA raised the firm’s price target on Moderna (MRNA) to $260 from $220 and keeps a Neutral rating on the shares after what the firm calls a “clean beat and

RBC Capital raised the firm’s price target on Moderna (MRNA) to $145 from $130 and keeps a Sector Perform rating on the shares. Published first on TheFly – the ultimate